Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

mTOR is required for pulmonary arterial vascular smooth muscle cell proliferation under chronic hypoxia.

Krymskaya VP, Snow J, Cesarone G, Khavin I, Goncharov DA, Lim PN, Veasey SC, Ihida-Stansbury K, Jones PL, Goncharova EA.

FASEB J. 2011 Jun;25(6):1922-33. doi: 10.1096/fj.10-175018.

2.

Anticancer efficacy of simvastatin on prostate cancer cells and tumor xenografts is associated with inhibition of Akt and reduced prostate-specific antigen expression.

Kochuparambil ST, Al-Husein B, Goc A, Soliman S, Somanath PR.

J Pharmacol Exp Ther. 2011 Feb;336(2):496-505. doi: 10.1124/jpet.110.174870.

3.

Apoptotic induction by simvastatin in human lung cancer A549 cells via Akt signaling dependent down-regulation of survivin.

Hwang KE, Na KS, Park DS, Choi KH, Kim BR, Shim H, Jeong ET, Kim HR.

Invest New Drugs. 2011 Oct;29(5):945-52. doi: 10.1007/s10637-010-9450-2.

PMID:
20464445
4.

Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony.

Foster KG, Fingar DC.

J Biol Chem. 2010 May 7;285(19):14071-7. doi: 10.1074/jbc.R109.094003. Review.

5.

Simvastatin induces derepression of PTEN expression via NFkappaB to inhibit breast cancer cell growth.

Ghosh-Choudhury N, Mandal CC, Ghosh-Choudhury N, Ghosh Choudhury G.

Cell Signal. 2010 May;22(5):749-58. doi: 10.1016/j.cellsig.2009.12.010.

6.

mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action.

Soliman GA, Acosta-Jaquez HA, Dunlop EA, Ekim B, Maj NE, Tee AR, Fingar DC.

J Biol Chem. 2010 Mar 12;285(11):7866-79. doi: 10.1074/jbc.M109.096222.

7.

mTOR signaling at a glance.

Laplante M, Sabatini DM.

J Cell Sci. 2009 Oct 15;122(Pt 20):3589-94. doi: 10.1242/jcs.051011. Review. No abstract available.

8.

Down-regulation of RhoA is involved in the cytotoxic action of lipophilic statins in HepG2 cells.

Maeda A, Yano T, Itoh Y, Kakumori M, Kubota T, Egashira N, Oishi R.

Atherosclerosis. 2010 Jan;208(1):112-8. doi: 10.1016/j.atherosclerosis.2009.07.033.

PMID:
19683239
9.

Signal transducer and activator of transcription 3 is required for abnormal proliferation and survival of TSC2-deficient cells: relevance to pulmonary lymphangioleiomyomatosis.

Goncharova EA, Goncharov DA, Damera G, Tliba O, Amrani Y, Panettieri RA Jr, Krymskaya VP.

Mol Pharmacol. 2009 Oct;76(4):766-77. doi: 10.1124/mol.109.057042.

10.

Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis.

Pollizzi K, Malinowska-Kolodziej I, Stumm M, Lane H, Kwiatkowski D.

Mol Cancer. 2009 Jun 15;8:38. doi: 10.1186/1476-4598-8-38.

11.

The pharmacology of mTOR inhibition.

Guertin DA, Sabatini DM.

Sci Signal. 2009 Apr 21;2(67):pe24. doi: 10.1126/scisignal.267pe24.

PMID:
19383975
12.

Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition.

Breuleux M, Klopfenstein M, Stephan C, Doughty CA, Barys L, Maira SM, Kwiatkowski D, Lane HA.

Mol Cancer Ther. 2009 Apr;8(4):742-53. doi: 10.1158/1535-7163.MCT-08-0668.

13.
14.

Rho GTPase function in tumorigenesis.

Karlsson R, Pedersen ED, Wang Z, Brakebusch C.

Biochim Biophys Acta. 2009 Dec;1796(2):91-8. doi: 10.1016/j.bbcan.2009.03.003. Review.

PMID:
19327386
15.

TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2.

Copp J, Manning G, Hunter T.

Cancer Res. 2009 Mar 1;69(5):1821-7. doi: 10.1158/0008-5472.CAN-08-3014.

16.

PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects.

Krymskaya VP, Goncharova EA.

Cell Cycle. 2009 Feb 1;8(3):403-13. Review.

17.

Safety and efficacy of statin therapy in patients switched from cyclosporine a to sirolimus after cardiac transplantation.

Aliabadi AZ, Mahr S, Dunkler D, Grömmer M, Zimpfer D, Wolner E, Grimm M, Zuckermann AO.

Transplantation. 2008 Dec 27;86(12):1771-6. doi: 10.1097/TP.0b013e3181910eb2.

PMID:
19104420
18.

Role for protein geranylgeranylation in adult T-cell leukemia cell survival.

Nonaka M, Uota S, Saitoh Y, Takahashi M, Sugimoto H, Amet T, Arai A, Miura O, Yamamoto N, Yamaoka S.

Exp Cell Res. 2009 Jan 15;315(2):141-50. doi: 10.1016/j.yexcr.2008.10.010.

PMID:
18992741
19.

HMG-CoA reductase inhibitor simvastatin overcomes bortezomib-induced apoptosis resistance by disrupting a geranylgeranyl pyrophosphate-dependent survival pathway.

Fuchs D, Berges C, Opelz G, Daniel V, Naujokat C.

Biochem Biophys Res Commun. 2008 Sep 19;374(2):309-14. doi: 10.1016/j.bbrc.2008.07.012.

PMID:
18625202
20.

In-vitro synergism of m-TOR inhibitors, statins, and classical chemotherapy: potential implications in acute leukemia.

Calabro A, Tai J, Allen SL, Budman DR.

Anticancer Drugs. 2008 Aug;19(7):705-12. doi: 10.1097/CAD.0b013e328304ae19.

PMID:
18594212
Items per page

Supplemental Content

Support Center